Combined Use of warfarin and oral P2Y12 inhibitors in patients with atrial fibrillation and acute coronary syndrome

Clinical Cardiology

Volumn 37, Issue 3, 2014, Pages 152-159

  Jones, W Schuyler ^a   Mi, Xiaojuan ^a   Patel, Manesh R ^a   Mills, Roger ^b   Hernandez, Adrian F ^a   Curtis, Lesley H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR INHIBITOR; UNCLASSIFIED DRUG; WARFARIN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; AGED; ARTICLE; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CELLULITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EXPOSURE; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HOSPITAL READMISSION; HUMAN; KIDNEY FAILURE; KIDNEY INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MORTALITY; OUTCOME ASSESSMENT; PLEURISY; PNEUMONIA; URINARY TRACT INFECTION; VERY ELDERLY;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASES; CELLULITIS; COMORBIDITY; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MEDICARE; MYOCARDIAL REVASCULARIZATION; PATIENT READMISSION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STENTS; THROMBOEMBOLISM; UNITED STATES; WARFARIN;

EID: 84896392755     PISSN: 01609289     EISSN: 19328737     Source Type: Journal    
DOI: 10.1002/clc.22231     Document Type: Article

References (31)

1. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011; 57: 1330-1337.
2. Jabre P, Roger VL, Murad MH, et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. Circulation. 2011; 123: 1587-1593.
3. Jabre P, Jouven X, Adnet F, et al. Atrial fibrillation and death after myocardial infarction: a community study. Circulation. 2011; 123: 2094-2100.
4. Lopes RD, Starr A, Pieper CF, et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. Am J Med. 2010; 123: 134-140.
5. Lopes RD, Pieper KS, Horton JR, et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart. 2008; 94: 867-873.
6. Lopes RD, Elliott LE, White HD, et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J. 2009; 30: 2019-2028.
7. Mehta RH, Dabbous OH, Granger CB, et al. GRACE Investigators. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. Am J Cardiol. 2003; 92: 1031-1036.
8. Rathore SS, Berger AK, Weinfurt KP, et al. Acute myocardial infarction complicated by atrial fibrillation in the elderly: prevalence and outcomes. Circulation. 2000; 101: 969-974.
9. Shireman TI, Howard PA, Kresowik TF, et al. Combined anticoagulant- antiplatelet use and major bleeding events in elderly atrial fibrillation patients. Stroke. 2004; 35: 2362-2367.
10. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006; 37: 1070-1074.
11. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006; 367: 1903-1912.
12. Singer DE, Albers GW, Dalen JE, et al. American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133 (6 suppl): 546S-592S.
13. Menozzi M, Rubboli A, Manari A, et al. Triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary artery stenting: hovering among bleeding risk, thromboembolic events, and stent thrombosis. Thromb J. 2012; 10: 22.
14. Anderson JL, Adams CD, Antman EM, et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011; 123: e426-e579.
15. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170: 1433-1441.
16. Sarafoff N, Ndrepepa G, Mehilli J, et al. Aspirin and clopidogrel with or without phenprocoumon after drug eluting coronary stent placement in patients on chronic oral anticoagulation. Am J Med. 2008; 264: 472-480.
17. Karjalainen PP, Porela P, Ylitalo A, et al. Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting. Eur Heart J. 2007; 28: 726-732.
18. Ruiz-Nodar JM, Marín F, Hurtado JA, et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis. J Am Coll Cardiol. 2008; 51: 818-825.
19. Rogacka R, Chieffo A, Michev I, et al. Dual antiplatelet therapy after percutaneous coronary intervention with stent implantation in patients taking chronic oral anticoagulation. JACC Cardiovasc Interv. 2008; 1: 56-61.
20. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting: an expert consensus document with focus on atrial fibrillation. Ann Med. 2008; 40: 428-436.
21. Lip GY, Huber K, Andreotti F, et al. European Society of Cardiology Working Group on Thrombosis. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost. 2010; 103: 13-28.
22. Centers for Medicare & Medicaid Services, Chronic Conditions Data Warehouse. Medicare Part D prescription drug data, Table F.1: Medicare Part D Beneficiary Counts, 2006-2011. http://www.ccwdata.org/cs/groups/public/ documents/document/wls-ucm1-000780.pdf. Published May 15, 2013. Accessed June 25, 2013.
23. Anderson JR, Cain KC, Gelber RD,. Analysis of survival by tumor response. J Clin Oncol. 1983; 1: 710-719.
24. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001; 285: 2864-2870.
25. Fuster V, Ryden LE, Cannom DS, et al. American College of Cardiology Foundation/American Heart Association Task Force. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011; 123: e269-e367.
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151.
27. Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891.
28. Granger CB, Alexander JH, McMurray JJ, et al. ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992.
29. Lip GY, Huber K, Andreotti F, et al. Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2010; 31: 1311-1318.
30. Fosbol EL, Wang TY, Li S, et al. Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction. Am Heart J. 2012; 163: 720-728.
31. Dewilde WJ, Oirbans T, Verheugt FW, et al. WOEST Study Investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381: 1107-1115.